Turkish Journal of Medical Sciences
Abstract
Background/aim: Coronavirus disease 2019 (COVID-19) shares some clinical features with new-onset granulomatosis with polyangiitis (GPA) or GPA flare that may lead to a challenge in differential diagnosis. To date, little is known whether GPA can be induced by COVID-19. Herein, we aimed to seek the frequency and mortality rates of COVID-19 in our GPA cohort, and along with the literature cases, to evaluate clinical features and treatments of GPA patients with COVID-19. We also tried to identify clinical features of COVID-19 induced GPA. Materials and methods: As of July 2021, we conducted a systematic literature review using different spelling combinations of "COVID-19 and GPA" in the PUBMED database. In total, 18 cases were found in the literature, 6 of them had COVID-19 induced GPA. T he remaining 12 of literature cases and 6 cases in our GPA cohort (n = 81) had a COVID-19 infection while followed-up with GPA. We grouped these 18 patients as GPA+COVID-19. Results: The frequency of COVID-19 was 7.4% in GPA cohort and mortality rate was 33% in GPA patients with COVID-19. The most common symptoms of GPA+COVID-19 patients were fever, cough, arthralgia/myalgia, and malaise. The most frequent treatments for GPA before the COVID-19 infection were steroids (72%) and rituximab (56%). Three patients who received rituximab also had COVID-19 reinfection. In the literature cases, mortality was observed in 4 (22%) of 18 patients with GPA+COVID-19. The most common symptoms of COVID-19 induced GPA were dyspnea, fever and cough. Conclusion: In our GPA cohort, we observed a higher mortality rate compared to global WHO data. In patients followed up with GPA, rituximab treatment may be precarious for both COVID-19 disease and reinfection. Our study also provided some clues about the diagnostic challenge of GPA induced by COVID-19.
DOI
10.55730/1300-0144.5389
Keywords
Coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, granulomatosis with polyangiitis, Wegener's granulomatosis, rituximab
First Page
899
Last Page
909
Recommended Citation
ARMAĞAN, B, EKSİN, M. A, GÜVEN, S. C, ÖZDEMİR, B, DAĞLI, P. A, KÜÇÜKŞAHİN, O, OMMA, A, & ERDEN, A (2022). COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. Turkish Journal of Medical Sciences 52 (4): 899-909. https://doi.org/10.55730/1300-0144.5389